Nonsteroidal anti-inflammatory drug

Award-Winning, FDA-Cleared Technology Uses Body's Own Fat to Help Heal Orthopedic Injuries

Retrieved on: 
木曜日, 1月 17, 2019
Endocrine system, Corticosteroids, Hepatotoxins, Hormones, Steroids, Nonsteroidal anti-inflammatory drug, Anti-inflammatory

The LIPOGEMS device rinses and cleans in effect screens out the unhealthy substances contained in adipose tissueoils and blood from the patient's harvested fat.

Key Points: 
  • The LIPOGEMS device rinses and cleans in effect screens out the unhealthy substances contained in adipose tissueoils and blood from the patient's harvested fat.
  • When injected into the treatment site, LIPOGEMS this allows for the body to heal the natural way using the patient's own fat.
  • "I started New Jersey Sports Medicine because I was interested in other options to major, invasive surgery for patients.
  • We knew corticosteroids and Nonsteroidal Anti-Inflammatory Drugs (NSAIDS) weren't very effective and potentially harmful to patients," Dr. Malanga said.

The Global Market for Rheumatoid Arthritis Drugs (2018-2022): Analysis by Type of Molecule, Type of RA, Region and Vendor

Retrieved on: 
金曜日, 12月 7, 2018
Medicine, Health, RTT, Rheumatology, Arthritis, Autoimmune diseases, Biotechnology, Rheumatoid arthritis, Disease-modifying antirheumatic drug, Biopharmaceutical, Nonsteroidal anti-inflammatory drug, Psoriatic arthritis

The "Global Rheumatoid Arthritis Drugs Market 2018-2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Rheumatoid Arthritis Drugs Market 2018-2022" report has been added to ResearchAndMarkets.com's offering.
  • The rheumatoid arthritis drugs market will register a CAGR of close to 8% by 2022.
  • The use of biologics and biosimilars for the treatment of RA is likely to help the market grow.
  • Unlike conventional DMARDs, such as nonsteroidal anti-inflammatory drugs (NSAIDs) that simply provide symptomatic relief, biologics are considered a more effective medication for management of rheumatoid arthritis.

Analgesics Market: North America to Remain Largest Revenue Market Throughout the Forecast Period: Global Industry Analysis 2013 - 2017 and Opportunity Assessment 2018 - 2028

Retrieved on: 
水曜日, 10月 10, 2018
Hepatotoxins, Medicine, Clinical medicine, Pharmacology, Pain, Antipyretics, Analgesics, Acetanilides, Paracetamol, Anti-inflammatory, Nonsteroidal anti-inflammatory drug, Opioid

The primary objective of the report is to offer updates and information related to market opportunities in the global analgesics market.

Key Points: 
  • The primary objective of the report is to offer updates and information related to market opportunities in the global analgesics market.
  • The Analgesics Market is Segmented Based on:
    This report covers the global analgesics market performance in terms of revenue contribution from various segments.
  • The market viewpoints section underlines macro-economic factors influencing the growth of the global analgesics market along with detailing the opportunity analysis of the market.
  • By drug class, the global analgesics market is segmented as opioids, non-steroidal anti-inflammatory drugs (NSAIDs), local anaesthetics and acetaminophen.

NSAIDs to Treat Arthritic Canines Through 2028; Stem Cell Therapies to Invigorate Canine Arthritis Treatment Market

Retrieved on: 
月曜日, 8月 6, 2018
Medicine, Health, Rheumatology, RTT, Clinical medicine, Hepatotoxins, Skeletal disorders, Nonsteroidal anti-inflammatory drug, Arthritis, Osteochondritis dissecans, Psoriatic arthritis

Additional factors like increasing number of veterinary clinics couple with stem cell transplants and Non-steroidal anti-inflammatory medications (NSAIDs) are likely to push the market for canine arthritis treatment.

Key Points: 
  • Additional factors like increasing number of veterinary clinics couple with stem cell transplants and Non-steroidal anti-inflammatory medications (NSAIDs) are likely to push the market for canine arthritis treatment.
  • Non-steroidal anti-inflammatory medications (NSAIDs) segment is expected to made substantial revenue contribution to overall canine arthritis treatment market followed by opioids during forecast period.
  • In terms of treatment, NSAIDs are continue to be the globally accepted mainstay of pharmaceutical treatment for canine arthritis, further shaping the canine arthritis treatment market.
  • FDA-approved MediVet's Autologous Stem Cell and Aratana's Galliprant to control pain and inflammation associated with arthritis, are expected to contribute to the growth of the canine arthritis treatment market."

SiteOne Therapeutics to Present Research Findings for Selective Small Molecule Nav1.7 Inhibitors at the 2018 World Congress on Pain

Retrieved on: 
木曜日, 7月 19, 2018
Pain, Pain management, Hepatotoxins, Nav1.7, Opioid, Chronic pain, Nonsteroidal anti-inflammatory drug

BOZEMAN, Mont., July 19, 2018 /PRNewswire/ --SiteOne Therapeutics, a private biopharmaceutical company advancing novel non-opioid pain therapeutics, announced today that the Company will present new preclinical data from its program developing novel selective small molecule Nav1.7 Inhibitors at the 17th World Congress on Pain, scheduled to take place in Boston, Massachusetts, September 12-16, 2018.

Key Points: 
  • BOZEMAN, Mont., July 19, 2018 /PRNewswire/ --SiteOne Therapeutics, a private biopharmaceutical company advancing novel non-opioid pain therapeutics, announced today that the Company will present new preclinical data from its program developing novel selective small molecule Nav1.7 Inhibitors at the 17th World Congress on Pain, scheduled to take place in Boston, Massachusetts, September 12-16, 2018.
  • "Since the inception of SiteOne Therapeutics, our team has prepared hundreds of new molecular entities targeting a unique binding site on Nav1.7.
  • SiteOne is dedicated to developing novel pain therapeutics to safely, effectively and efficiently treat acute and chronic pain without the limitations of existing pain therapies, such as NSAIDs or opioids.
  • The company's therapeutic candidates are highly selective sodium ion channel 1.7 (Nav1.7) inhibitors based on naturally occurring small molecules.

Veterinary Pain Management Market - Global Forecast to 2023

Retrieved on: 
月曜日, 4月 30, 2018
Pain, Perception, Acute pain, Hepatotoxins, RTT, Arthritis, Osteoarthritis, Pain management, Nonsteroidal anti-inflammatory drug, Opioid

The "Veterinary Pain Management Market by Product (Drugs (NSAIDs, Opioids), Device (Laser, Electromagnetic)), Application (Osteoarthritis, Cancer), Animal Type (Dog, Cat, Horse, Cattle), Distribution Channel (Hospital, Pharmacy) - Global Forecast to 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Veterinary Pain Management Market by Product (Drugs (NSAIDs, Opioids), Device (Laser, Electromagnetic)), Application (Osteoarthritis, Cancer), Animal Type (Dog, Cat, Horse, Cattle), Distribution Channel (Hospital, Pharmacy) - Global Forecast to 2023" report has been added to ResearchAndMarkets.com's offering.
  • The veterinary pain management market is projected to reach USD 1.66 Billion by 2023 from USD 1.13 Billion in 2018, at a CAGR of 8.0% during the forecast period.
  • By application, the veterinary pain management market has been segmented into joint pain, postoperative pain, cancer, and other applications.
  • By animal type, the global veterinary pain management market is segmented into companion and livestock animals.

Veterinary Pain Management Market Worth 1.66 Billion USD by 2023

Retrieved on: 
金曜日, 4月 20, 2018
Pain, Perception, Medicine, RTT, Skeletal disorders, Acute pain, Hepatotoxins, Pain management, Osteoarthritis, Nonsteroidal anti-inflammatory drug, Arthritis, Opioid

According to a new market research report "Veterinary Pain Management Market by Product (Drugs (NSAIDs, Opioids), Device (Laser, Electromagnetic), Application (Osteoarthritis, Cancer), Animal Type (Dog, Cat, Horse, Cattle), Distribution Channel (Hospital, Pharmacy)) - Global Forecast to 2023", published by MarketsandMarkets, the market is projected to reach USD 1.66 Billion by 2023 from USD 1.13 Billion in 2018, at a CAGR of 8.0% during the forecast period.

Key Points: 
  • According to a new market research report "Veterinary Pain Management Market by Product (Drugs (NSAIDs, Opioids), Device (Laser, Electromagnetic), Application (Osteoarthritis, Cancer), Animal Type (Dog, Cat, Horse, Cattle), Distribution Channel (Hospital, Pharmacy)) - Global Forecast to 2023", published by MarketsandMarkets, the market is projected to reach USD 1.66 Billion by 2023 from USD 1.13 Billion in 2018, at a CAGR of 8.0% during the forecast period.
  • Based on application, the Veterinary Pain Management Market has been segmented into joint pain, postoperative pain, cancer, and other applications.
  • In 2017, joint pain held the largest share of the Veterinary Pain Management Market.
  • Global Veterinary Pain Management Market has been studied for North America, Europe, Asia Pacific (APAC), Latin America, and Middle East & Africa.